Navigation Links
Yale researchers develop a way to monitor engineered blood vessels as they grow in patients
Date:11/30/2011

Bethesda, MDUsing magnetic resonance imaging (MRI) and nanoparticle technology, researchers from Yale have devised a way to monitor the growth of laboratory-engineered blood vessels after they have been implanted in patients. This advance represents an important step toward ensuring that blood vessels, and possibly other tissues engineered from a patient's own biological material, are taking hold and working as expected. Until now, there has been no way to monitor the growth and progress of engineered tissues once they were implanted. This research was published in the December 2011 issue of the FASEB Journal (http://www.fasebj.org).

"We hope that the important findings from our study will serve as a valuable tool for physicians and scientists working to better understand the biological mechanisms involved in tissue engineering," said Christopher K. Breuer, M.D., co-author of the study from the Interdepartmental Program in Vascular Biology and Therapeutics at Yale University School of Medicine in New Haven, CT. "Resulting advances will hopefully usher in a new era of personalized medical treatments where replacement vessels are specifically designed for each patient suffering from cardiac anomalies and disease."

To make this advance, scientists used two different groups of cells to make tissue-engineered blood vessels. In the first group, the cells were labeled with the MRI contrast agent. In the second group, the cells were normal and did not have an MRI label. Cells from each group were then used to create separate laboratory-engineered blood vessels, which were implanted into mice. The purpose was to see whether the laboratory-engineered blood vessels made from cells that were labeled with the contrast agent would indeed be visible on MRI and to make sure that the addition of the contrast agent did not negatively affect the cells or the function of the laboratory-engineered vessels. Researchers imaged the mice with MRI and found that it was possible to track the cells labeled with contrast agent, but not possible to track the cells that were not labeled. This suggests that using MRI and cellular contrast agents to study cellular changes in the tissue-engineered blood vessels after they are implanted is an effective way to monitor these types of vessels.

"This is great news for patients with congenital heart defects, who have to undergo tissue grafting, but that's only the tip of the scalpel," said Gerald Weissmann, M.D., Editor-in-Chief of the FASEB Journal. "As we progress toward an era of personalized medicinewhere patients' own tissues and cells will be re-engineered into replacement organs and treatmentswe will need noninvasive ways to monitor what happens inside the body in real time. This technique fulfills another promise of nanobiology."


'/>"/>

Contact: Cody Mooneyhan
cmooneyhan@faseb.org
301-634-7104
Federation of American Societies for Experimental Biology
Source:Eurekalert

Related biology news :

1. NJIT researchers publish news of success with robots as learning tool
2. Researchers new recipe cooks up better tissue phantoms
3. BUSM researchers develop blood test to detect membranous nephropathy
4. WSU researchers use a 3-D printer to make bone-like material
5. Abstinence-only education does not lead to abstinent behavior, UGA researchers find
6. Body rebuilding: Researchers regenerate muscle in mice
7. UCLA researchers engineer blood stem cells to fight melanoma
8. BWH researchers develop a vaccine prototype stronger than traditional vaccines
9. The immune system has protective memory cells, researchers discover
10. Researchers awarded $3.2 million from NIH to pioneer advanced biomolecule discovery technology
11. 3 researchers in the Amazon clear up doubts as to the benefits of ecotourism
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/7/2017)... , Feb. 7, 2017 Zimmer Biomet Holdings, ... musculoskeletal healthcare, will present at the LEERINK Partners 6th ... Palace Hotel on Wednesday, February 15, 2017 at 10 ... of the presentation can be accessed at http://wsw.com/webcast/leerink28/zbh ... the conference via Zimmer Biomet,s Investor Relations website at ...
(Date:2/6/2017)... DENVER , Feb. 6, 2017 ... national security are driving border authorities to continue ... Acuity reports there are 2143 Automated Border Control ... Kiosks currently deployed at more than 163 ports ... between 2013 to 2016 achieving a combined CAGR ...
(Date:2/3/2017)... , Feb. 3, 2017 A new ... Identity Strategy Partners, LLP (IdSP) . Designed to fill ... the complex identity market, founding partners Mark Crego ... 35 combined years just in identity expertise that span ... and non-profit leadership. The Crego-Kephart combined expertise has a ...
Breaking Biology News(10 mins):
(Date:2/28/2017)... ... February 28, 2017 , ... RoviSys, a leading independent provider ... has joined the Cisco® Digital Solutions Integrator Program. As a member of this ... that addresses Industrial IT and Business IT in manufacturing environments. , John ...
(Date:2/28/2017)... ... February 28, 2017 , ... Over 8,000 recognized rare diseases afflict an ... webinar on March 7, DrugDev will gather international experts to share challenges ... area. , Webinar: Overcoming the Challenges of Rare Disease Clinical Trials, Date: March ...
(Date:2/28/2017)... ... February 28, 2017 , ... ... therapeutics from millions-diverse immune repertoires, today announced a strategic partnership with Trianni, ... engineered to express human antibodies. The partnership will use GigaGen technology to discover ...
(Date:2/28/2017)... LONDON and PHILADELPHIA , ... Pharma"), a privately held biopharmaceutical company focusing on debilitating ... treatment options, today announced that the company joins with ... leaders in patient advocacy and support around the world ... to highlight the unique challenges and needs of the ...
Breaking Biology Technology: